Active-ingredient Dossier
Abiraterone Acetate
Active-ingredient Dossier for Abiraterone Acetate (androgen synthesis inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled by…
- Brand: ANDRIGA-10
- Brand: YONSA
- Brand: ZYTIGA
- Brand: ANDRIGA-5
- Brand: ABIRATERONE
- Brand: ABIRATERONE
- Therapeutic area: Oncology
What is
Abiraterone Acetate Abiraterone Acetate is an androgen synthesis inhibitor.
Australian brands containing
Abiraterone Acetate — ZYTIGA — ANDRIGA-10 — YONSA — ABIRATERONE — ABIRATERONE SANDOZ — ABIRATERONE VIATRIS — ABIRATERONE-TEVA — ABYGA — ANDRIGA-5 — ARX-ABIRATERONE — ABIRATERONE-DRLA
Therapeutic areas
Abiraterone Acetate is registered in oncology, with 19 brands containing this ingredient on the ARTG.
Sponsor landscape
The ingredient is marketed by 11 sponsors, including Dr Reddys Laboratories, Nova Pharmaceuticals, Devatis, Glenmark Pharmaceuticals, Actor Pharmaceuticals, and Sandoz.
PBS and regulatory activity
One brand containing abiraterone acetate has PBS-listed items, with the latest PBS schedule date of 1 May 2026. The latest PBAC outcome was recorded on 1 July 2025, with 3 brands having PBAC outcomes on record. The latest AusPAR was published on 24 March 2022.